1. Generics Bulletin
  2. >>Products

Padagis Launches First-To-Market Zomig Nasal Spray Ahead Of Lannett

Follows Recent Deal With Sol-Gel For Rights Related To 10 Collaborative Agreements

 
• By Dean Rudge

Less than six months into life as an independent company, former Perrigo Rx unit Padagis has realized its second generic launch, with the first-to-market entry of generic Zomig (zolmitriptan) nasal spray.

Headache Migraine Pain
Patent protection ended in May • Source: Alamy

Padagis, the former Perrigo ‘Rx’ prescription pharmaceuticals business that was acquired by private equity in July this year, has swiftly realized its “second major product launch as an independent organization,” with the first-to-market entry of generic Zomig (zolmitriptan) nasal spray in the US.

According to the US Food and Drug Administration’s database of approved drug products, the former Perrigo business has received final approval for an AB-rated generic version of AstraZeneca/Amneal’s reference

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin

Medicines UK Welcomes NHS England’s Best-Value Biologics Biosimilar Adoption Framework

 
• By Adam Zamecnik

Reflecting on recent initiatives by NHS England and the MHRA, the newly renamed trade body Medicines UK has welcomed efforts in promoting the use of biosimilars in Britain.

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 
• By Urtė Fultinavičiūtė

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.